How Does Citicoline Treat Acute Craniocerebral Trauma And Consciousness Disorders After Brain Surgery
Citicoline is a neuroprotective and reparative agent that plays an important role in the treatment of acute traumatic brain injury and postoperative consciousness disorders. Its mechanism of action and clinical application are as follows:
Mechanism of action
Repair cell membrane
As a precursor for phosphatidylcholine synthesis, it promotes the repair of damaged neuronal cell membranes and stabilizes membrane structure.
Protecting mitochondrial function
Increase ATP energy supply within brain cells, improve cellular metabolism, and alleviate secondary brain injury.
Reduce free radical damage
Inhibit lipid peroxidation and alleviate the damage of oxidative stress to nerve cells.
Promote neurotransmitter synthesis
Raising acetylcholine and dopamine levels, improving nerve conduction, and helping to restore consciousness.
Clinical application
- Acute traumatic brain injury
Applicable stage: mainly used in the acute phase (within 24-72 hours) and recovery period after injury.
Treatment objective:
Reduce brain edema and inflammatory response.
Promote neurological function recovery and shorten coma time.
Reduce disability rates and the risk of cognitive sequelae.
Medication plan (reference):
Intravenous administration: 500-1000mg/time, 1-2 times a day, treatment course 2-4 weeks.
Severe patients: can be increased to 2000mg per day, administered in divided doses.
- Postoperative consciousness disorders
Applicable situations: delayed anesthesia recovery, postoperative coma, cognitive dysfunction, etc.
Function:
Accelerate the clearance of anesthetic metabolites.
Improve cerebral blood flow and oxygenation, promote consciousness recovery.
Reduce postoperative delirium or cognitive decline.
Medication plan:
Preoperative prevention: Immediately administer 500-1000mg intravenously after surgery.
Postoperative treatment: 1000-2000mg per day for 7-14 days, adjusted according to the recovery of consciousness.
Efficacy basis
Evidence based medicine:
International multicenter studies, such as the TABASCO trial, have shown that phosphatidylcholine can improve cognitive function and quality of life in patients with traumatic brain injury.
Studies on stroke and brain surgery patients have shown that it can shorten the duration of consciousness disorders and improve Glasgow Coma Scale (GCS).
Recommended Chinese Guide:
The Chinese Guidelines for Diagnosis and Treatment of Craniocerebral Trauma list phosphatidylcholine as an adjuvant medication for neuroprotective therapy (Grade II recommendation).
Precautions
Contraindications
Use with caution in patients with ingredient allergies, severe bradycardia, and hypotension.
Adverse reactions
Occasional nausea and temporary decrease in blood pressure (when administered too quickly), slow intravenous infusion (>30 minutes) is recommended.
Combination therapy
Often used in combination with dehydrating agents (mannitol) and neurotrophic drugs (gangliosides), the dosage should be adjusted according to medical advice.
Suggestions for patients/family members
Early intervention: Use within 48 hours after brain injury for better results.
Adequate treatment course: The medication should be continued for 2-4 weeks and should not be discontinued on its own.
Comprehensive treatment: rehabilitation training (such as hyperbaric oxygen and acupuncture and moxibustion) is needed to optimize the curative effect.
Summary
Phosphatidylcholine effectively promotes the recovery of consciousness and neurological function in patients with acute traumatic brain injury and brain surgery by repairing nerve cell membranes, improving energy metabolism, and antioxidant properties. As an adjuvant therapy, it should be used in a standardized manner under the guidance of a doctor and integrated into comprehensive neurological rehabilitation management. The specific medication plan should be formulated by neurosurgeons or critical care physicians based on the individual situation of the patient.
